Autosomal dominant diabetes associated with a novel ZYG11A mutation resulting in cell cycle arrest in beta-cells

Charoensuk, Chutima; Thamtarana, Prapaporn Jungtrakoon; Chanprasert, Chutima; Tangjittipokin, Watip; Shirakawa, Jun; Togashi, Yuichi; Orime, Kazuki; Songprakhon, Pucharee; Chaichana, Chartchai; Abubakar, Zuroida; Ouying, Paweena; Sujjitjoon, Jatuporn; Doria, Alessandro; Plengvidhya, Nattachet; Yenchitsomanus, Pa‐thai

doi:10.1016/j.mce.2020.111126

Cited by 3 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, abrogation of ZYG11A expression led to a decrease in cyclin D1 levels and enhanced p53 and p21 concentrations. Likewise, ZYG11A was shown to function as a cell cycle regulator required for b-cell growth (25). ZYG11A-deficient b-cells were arrested at the G2/M phase of the cell cycle, leading to a drastic reduction in growth rate.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

ZYG11A Is Expressed in Epithelial Ovarian Cancer and Correlates With Low Grade Disease

Achlaug¹,

Somri-Gannam²,

Meisel-Sharon³

et al. 2021

Front. Endocrinol.

View full text Add to dashboard Cite

The insulin-like growth factors (IGF) are important players in the development of gynecological malignancies, including epithelial ovarian cancer (EOC). The identification of biomarkers that can help in the diagnosis and scoring of EOC patients is of fundamental importance in clinical oncology. We have recently identified the ZYG11A gene as a new candidate target of IGF1 action. The aim of the present study was to evaluate the expression of ZYG11A in EOC patients and to correlate its pattern of expression with histological grade and pathological stage. Furthermore, and in view of previous analyses showing an interplay between ZYG11A, p53 and the IGF1 receptor (IGF1R), we assessed a potential coordinated expression of these proteins in EOC. In addition, zyg11a expression was assessed in ovaries and uteri of growth hormone receptor (GHR) knock-out mice. Tissue microarray analysis was conducted on 36 patients with EOC and expression of ZYG11A, IGF1R and p53 was assessed by immunohistochemistry. Expression levels were correlated with clinical parameters. qPCR was employed to assess zyg11a mRNA levels in mice tissues. Our analyses provide evidence of reduced ZYG11A expression in high grade tumors, consistent with a putative tumor suppressor role. In addition, an inverse correlation between ZYG11A and p53 levels in individual tumors was noticed. Taken together, our data justify further exploration of the role of ZYG11A as a novel biomarker in EOC.

show abstract

Section: Discussionmentioning

confidence: 99%

“…In agreement with this finding, increased ZYG11A expression in this condition was correlated with a poor prognosis. In addition, a recent study generated evidence that a missense mutation of the ZYG11A gene caused cell cycle arrest in pancreatic b-cells, linking malfunction of this gene to chronic hyperglycemia (25).…”

Section: Introductionmentioning

confidence: 99%